Patrick Lin bought $9,525 of PCSA
Chief Business - Strategy Off at Processa Pharmaceuticals, Inc.. 4,000 shares at an average of $2.38, traded Jan 31, 2024, filed Feb 1, 2024.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- +3Relative to holdingsHoldings up 17%
- +8Price context88% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.1%, 3m -3.4%, 6m -10.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000897069-24-000236, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2024 | POpen-market purchase Common Stock | +2,500 | $2.37 | $5,925 | 25,978 | Feb 1, 2024 |
| Feb 1, 2024 | POpen-market purchase Common Stock | +1,500 | $2.40 | $3,600 | 27,478 | Feb 1, 2024 |
Related signals
Other insiders at Processa Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 59Moderate | Processa Pharmaceuticals, Inc. | Wendy Guy Chief Administrative Officer | $4,701 2,436 shares | +20% | |
| 56Moderate | Processa Pharmaceuticals, Inc. | Patrick Lin Chief Business - Strategy Off | $4,065 2,106 shares | +19% | |
| 69Notable | Processa Pharmaceuticals, Inc. | George K Ng Chief Executive Officer | $5,900 3,057 shares | +25% | |
| 56Moderate | Processa Pharmaceuticals, Inc. | David Young Pres. Research & Development | $4,885 2,531 shares | +13% | |
| 66Notable | Processa Pharmaceuticals, Inc. | Russell Skibsted Chief Financial Officer | $6,325 3,277 shares | +24% | |
| 49Moderate | Processa Pharmaceuticals, Inc. | Wendy Guy Chief Administrative Officer | $4,702 2,118 shares | +22% | |
| 46Moderate | Processa Pharmaceuticals, Inc. | Patrick Lin Chief Business - Strategy Off | $4,065 1,831 shares | +20% | |
| 59Moderate | Processa Pharmaceuticals, Inc. | George K Ng Chief Executive Officer | $5,472 2,465 shares | +25% | |
| 56Moderate | Processa Pharmaceuticals, Inc. | Russell Skibsted Chief Financial Officer | $5,892 2,654 shares | +25% | |
| 46Moderate | Processa Pharmaceuticals, Inc. | David Young Pres. Research & Development | $4,589 2,067 shares | +12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.